CRCbioscreen announced today that Henri Theunissen has been appointed CEO of the company. An experienced business leader, Theunissen will complement CRCbioscreen’s management team that further consists of Meike de Wit as COO and Gerrit Meijer as CSO.
“As an innovation expert and seasoned entrepreneur with extensive science business experience in biotech and pharma, and having started and grown 30+ companies, Theunissen is the right fit for our company” said Gerrit Meijer, CSO and co-founder.
“His experience and competences will be important for further developing CRCbioscreen as a company, as well as developing its unique multi-target FIT into a commercial product for superior colorectal cancer screening” said Meike de Wit, COO and co-founder.
Henri graduated in Biology (Radboud University Nijmegen), holds a PhD in Molecular Biology (NKI, University of Amsterdam) and was a postdoc in Immunohaematology (Central Lab of Blood Transfusion, Amsterdam). As of 1990, he worked at Organon International (later Schering-Plough and Merck) in the Cardiovascular and Reproductive Medicine programs and as head of the Genomics & Bioinformatics group. As an expat in Cambridge (MA, USA) he focused on biotechnology, immunology, and oncology as a Senior Director, Global Strategy, Portfolio Management and Research Alliances, and as Vice President and Officer of Diosynth RTP (NC, USA). He was also an MT member of Nobilon BV (Boxmeer) for Business Development and Strategic Marketing of human vaccines. As of 2009 he worked as the CEO of BioMedBooster, later Knowledge Transfer Funds BV, Chief Valorisation Officer of Maastricht University, and Chief Innovation Officer of Brightlands Maastricht Health Campus. Since 2021 he is CEO and Founder of IMC Innovation Management & Consultancy BV.